A Phase 2b Study to Select a Once Daily Oral Dose of GSK2248761 in HIV-1 Infected Antiretroviral Therapy Experienced Adults With Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Resistance
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009185/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This 48 week, phase 2b study in 150 HIV-1 infected antiretroviral therapy experienced adult
subjects consists of a dose-ranging evaluation of GSK2248761 at blinded doses of 100 mg and
200 mg once daily with a control arm of open-label etravirine (ETV) 200 mg twice daily. The
background ART for all three arms will be darunavir/ritonavir (DRV/r) 600 mg/100 mg twice
daily plus raltegravir (RAL) 400 mg twice daily. Antiviral activity, safety, PK, and
development of viral resistance will be evaluated.
提供机构：
Vivli
创建时间：
2023-08-15
